| Variable | Patients (n = 94) | Companions (n = 39) | p value |
| Sex n (%) | 0.002 | ||
| Male | 49 (52.1) | 9 (23.1) | |
| Female | 45 (47.9) | 30 (76.9) | |
| Age, Years n (%) | |||
| <60 | 73 (76.3) | 31 (79.5) | 0.694 |
| ≥60 | 22 (23.7) | 8 (20.5) | |
| Mean (SD) Median (Range) | 53.7 (8.0) 55.2 (29.4 - 65.7) | 46.9 (15.0) 50.1 (18.4 - 67.9) | 0.043a |
| Cohabiting partner n (%) | 0.427 | ||
| Yes | 57 (62.0) | 27 (69.2) | |
| No | 12 (38.0) | 12 (30.8) | |
| Years of school n (%) | |||
| 4 to 8 | 45 (47.9) | 12 (30.8) | 0.157 |
| 9 to 11 | 25 (26.6) | 13 (33.3) | |
| 12 to 17 | 17 (18.1) | 7 (17.9) | |
| ≥18 | 7 (7.4) | 7 (17.9) | |
| Mean (SD) Median (Range) | 10.0 (4.7) 9.5 (4 - 29) | 11.5 (5.3) 11.0 (4 - 27) | 0.115a |
| Cancer Type n (%) | - | ||
| Lung | 5 (5.3) | - | |
| Breast | 15 (15.9) | - | |
| Pancreatic | 6 (6.4) | - | |
| Colorectal | 45 (47.8) | - | |
| Stomach | 8 (8.5) | - | |
| Bladder | 4 (4.2) | - | |
| Other | 10 (11.9) | ||
| Metastasis number n = 89 (%) | - | ||
| 1 | 67 (75.3) | - | |
| 2 | 15 (16.9) | - | |
| 3 or 4 | 7 (7.8) | ||
| Metastasis n = 89b (%) | - | ||
| Liver | 43 (48.3) | - | |
| Lung | 20 (22.5) | - | |
| Bone | 11 (12.4) | - | |
| Peritoneum | 8 (9.0) | - | |
| Ovarian | 2 (2.2) | ||
| Other | 19 (21.3) | - | |
| Unknown | 16 (18.0) | ||
| Present anticancer treatment (n = 94) | - | ||
| No treatment | 2 (2.2) | - | |
| Receiving treatment (n = 92) | 92 (97.9) | - | |
| Chemotherapy | 90 (95.7) | - | |
| Chemo and radiotherapy or hormone | 2 (2.2) | ||
| Karnofsky performance status (n = 68) | - | ||
| 100% - 80% | 58 (85.3) | - | |
| 70% or less | 10 (11.2) |